How do I transition oncology patients from intravenous immunoglobulin to subcutaneous immunoglobulin in an outpatient clinic?
Transfusion · 2026
DOI: 10.1111/trf.70353 ↗At a glance
Journal article in Transfusion, 2026. Written by Dior Caruso and 4 co-authors. Institution: Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Major MEDLINE topics: Immunoglobulins, Intravenous, Immunologic Deficiency Syndromes, Neoplasms. 25 references.
Abstract (original language)
Background
Intravenous immunoglobulin (IVIG) treating secondary immunodeficiency (SID) for oncology patients causes strain for outpatient clinic capacity. Home‐based subcutaneous immunoglobulin (SCIG) offers equivalent efficacy and improves patient convenience and resource utilization. Transition to home‐based SCIG remains infrequent due to fragmented referral pathways, limited clinician awareness, and inconsistent patient education. The project objective was to increase the number of patients transitioning from IVIG to SCIG.
Methods
A quality improvement initiative was established following a baseline assessment of the SCIG transition process and IVIG utilization patterns. A driver diagram informed change ideas tested across seven Plan–Do–Study–Act (PDSA) cycles. The outcome measure was the monthly SCIG referral rate. The process measures were the median monthly number of chronic, new start, and total IVIG users in the outpatient clinic. The balancing measures assessed if SCIG referrals had an effect on chair time and operational costs. Electronic referral process was developed, clinician education enhanced, nurse champion role created, and clinician and patient education materials were standardized.
Results
Following the intervention, the number of patients transitioning from IVIG to SCIG increased from 3.7% to 8.5%. The number of monthly new start IVIG users remained the same while the number of monthly chronic IVIG users increased. The balancing measures indicate that SCIG referrals did not reduce chair time but generated significant cost avoidance.
Discussion
Transitions from IVIG to SCIG have shifted care into the home, reducing outpatient pressure and costs. Long‐term sustainability requires improved referral of chronic IVIG users and strategies to support patient engagement.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
- Division of Cancer, Quality and Innovation, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Department of Clinical Pathology, University Health Network, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
ORCID profiles: Dior Caruso, Hilary Weatherby, Lani Lieberman
Cite
APA
Caruso, D., Weatherby, H., Rosario, S., Dozois, G., & Lieberman, L. (2026). How do I transition oncology patients from intravenous immunoglobulin to subcutaneous immunoglobulin in an outpatient clinic?. Transfusion. https://doi.org/10.1111/trf.70353
Vancouver
Caruso D, Weatherby H, Rosario S, Dozois G, Lieberman L. How do I transition oncology patients from intravenous immunoglobulin to subcutaneous immunoglobulin in an outpatient clinic?. Transfusion. 2026. doi:10.1111/trf.70353
BibTeX
@article{Caruso2026,
author = {Caruso, Dior and Weatherby, Hilary and Rosario, Schenell and Dozois, Graham and Lieberman, Lani},
title = {How do I transition oncology patients from intravenous immunoglobulin to subcutaneous immunoglobulin in an outpatient clinic?},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.70353}
}
EUVIMED